Immunosuppressive effect on T cell activation by interleukin-16- and interleukin-10-cDNA-double-transfected human squamous cell line

Burns

Volumn 35, Issue 3, 2009, Pages 383-389

  Matsumoto, Yoshitaka ^a   Fujita, Tatsuya ^a   Hirai, Itaru ^a   Sahara, Hiroeki ^a   Torigoe, Toshihiko ^a   Ezoe, Kyori ^a   Saito, Tamotsu ^a   Cruikshank, William W ^b   Yotsuyanagi, Takatoshi ^a   Sato, Noriyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic skin graft; Artificial skin; Gene therapy; Interleukin 10; Interleukin 16

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 10; INTERLEUKIN 16;

ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; GENETIC TRANSFECTION; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KERATINOCYTE; MIXED LYMPHOCYTE REACTION; PROTEIN SYNTHESIS; SKIN ALLOGRAFT; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; GENETICS; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; PROCEDURES; SKIN TRANSPLANTATION; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; INTERLEUKIN-10; INTERLEUKIN-16; LYMPHOCYTE ACTIVATION; SKIN TRANSPLANTATION; T-LYMPHOCYTES; TRANSFECTION;

EID: 61549143721     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.burns.2008.06.017     Document Type: Article

References (48)

1. Brown J.B., Minot P.F., and Randall P. Postmortem homograft as "biological dressing" for extensive burns and denuded areas. Ann Surg 138 (1953) 618-629
2. Zaroff L.I., Mills W., Duckett J.W., Switzer W.E., and Moncrief J.A. Multiple uses of viable cutaneous homografts in the burned patient. Surgery 59 (1966) 368-372
3. Spence R.J., and Wong L. The enhancement of wound healing with human skin allograft. Surg Clin North Am 77 (1977) 731-745
4. Fujita T., Matsumoto Y., Hirai I., Ezoe K., Saito T., Yagihashi A., et al. Immunosuppressive effect on T cell activation by interleukin-16-cDNA-transfected human squamous cell line. Cell Immunol 202 (2000) 54-60
5. Bejarano M.T., de Waal Malefyt R., Abrams J.S., Bigler M., Bacchetta R., de Vries J.E., et al. IL-10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary MLR. Int Immunol 4 (1992) 1389-1397
6. Miyazaki A., Sato N., Takahashi S., Sasaki A., Kohama G., Yamaguchi A., et al. Cytotoxicity of histocompatibility leukocyte antigen-DR8-restricted CD4+ killer T cells against human autologous squamous cell carcinoma. Jpn J Cancer Res 88 (1997) 191-197
7. Yokoi T., Hirata S., Nishimura F., Miyakawa A., Odajima T., Kohama G., et al. Some properties of a newly established human cell line derived from an oral squamous carcinoma. Tumor Res 25 (1990) 93-103
8. Morgenstein J.P., and Land H. Advanced mammalian gene transfer; high titer retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 18 (1990) 3587-3596
9. Cho J.M., Sato N., Yagihashi A., et al. Natural killer target molecules associated with the transformation of the oncogene-transformed fibroblast. Cancer Res 51 (1991) 4250-4256
10. Brodsky F.M., Bodmer W.F., and Parham P. Characterization of a monoclonal anti-beta 2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens. Eur J Immunol 9 (1979) 536-545
11. Smith L.M., Petty H.R., Parham P., and McConnell H.M. Cell surface properties of HLA antigens on Epstein-Barr virus-transformed cell lines. Proc Natl Acad Sci USA 79 (1982) 608-612
12. Moore K.W., O'Garra A., de Waal Malefyt R., Vieira P., and Mosmann T.R. Interleukin-10. Annu Rev Immunol 11 (1993) 165-190
13. Peters W.J. Biological dressings in burns-a review. Ann Plast Surg 4 (1980) 133-137
14. Alexander J.W., Wheeler L.M., Rooney R.C., McDonald J.J., and MacMillan B.G. Clinical evaluation of epigard, a new synthetic substitute for homograft and heterograft skin. J Trauma 13 (1973) 374-383
15. Friedman S.J., and Su W.P.D. Management of leg ulcers with hydrocolloid occlusive dressing. Arch Dermatol 120 (1984) 1329-1336
16. Albanesi C., Cavani A., and Girolomoni G. Interferon-γ stimulated human keratinocytes express the genes necessary for the production of peptide-loaded MHC class II molecules. J Invest Dermatol 110 (1988) 138-142
17. Tamura Y., Tsuboi N., Sato N., and Kikuchi K. 70 kDa heat shock cognate protein is a transformation-associated antigen and a possible target for the host's anti-tumor immunity. J Immunol 151 (1993) 5516-5524
18. Yamaki T., Uede T., Shijubo N., and Kikuchi K. Functional analysis of mononuclear cells infiltrating into tumors. III. Soluble factors involved in the regulation of T lymphocyte infiltration into tumors. J Immunol 140 (1988) 4388-4396
19. Fujita T., Takahashi S., Yagihashi A., Jimbow K., and Sato N. Prolonged survival of rat skin allograft by treatment with FK506 ointment. Transplantation 64 (1997) 922-925
20. Cruikshank W.W., Kornfeld H., and Center D.M. Signaling and functional properties of interleukin-16. Int Rev Immunol 16 (1988) 523-540
21. Cruikshank W.W., Center D.M., Nisar N., Wu M., Natke B., Theodore A.C., et al. Molecular and functional analysis of a lymphocyte chemoattractant factor; association of biological function with CD4 expression. Proc Natl Acad Sci USA 91 (1994) 5109-5113
22. Theodore A.C., Center D.M., Nicoll J., Fine G., Kornfeld H., and Cruikshank W.W. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J Immunol 59 (1996) 1958-1964
23. Fiorentino D.F., Bond M.W., and Mosmann T.R. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170 (1989) 2081-2095
24. Vieira P., de Waal-Malefyt R., Dang M.N., Johnson K.E., Kastelein R., Fiorentino D.F., et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 88 (1991) 1172-1176
25. Fiorentino D.F., Zlotnik A., Vierira P., Howard M., and O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146 (1991) 3444-3451
26. Taga K., and Tosato G. IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 148 (1992) 1143-1148
27. de Waal Malefyt R., Abrams J., Bennet B., Figdor C.G., and de Vries J.E. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174 (1991) 1209-1220
28. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., and O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 147 (1991) 3815-3822
29. Cassatella M.A., Meda L., Bonora S., Ceska M., and Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1β in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 178 (1993) 2207-2211
30. Kasama T., Strieter R.M., Lukacs N.W., Burdick M.D., and Kunkel S.L. Regulation of neutrophil derived chemokine expression by IL-10. J Immunol 152 (1994) 3559-3569
31. de Waal-Malefyt R., Haanen J., Spits H., Roncarolo M.G., te Velde A., Figdor C., et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174 (1991) 915-924
32. Drazan K.E., Wu L., Bullington D., and Shaked A. Viral IL-10 gene therapy inhibits TNF-a and IL-1b, not IL-6, in the newborn endotoxemic mouse. J Pediatr Surg 31 (1996) 411-414
33. Xing Z., Ohkawara Y., Jordana M., Graham F.L., and Gauldie J. Adenoviral vector-mediated interleukin-10 expression in-vivo: intramuscular gene transfer inhibits cytokine responses in endotoxemia. Gene Ther 4 (1997) 140-149
34. Gerard C., Bruyns C., Marchant A., Abramowicz D., Vandenabeele P., Delvaux A., et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177 (1993) 547-550
35. Pajkrt D., Camoglio L., Tiel-van Buul M.C., de Bruin K., Cutler D.L., Affrime M.B., et al. Attenuation of proinflammatory responses by recombinant human IL-10 in human endotoxemia. J Immunol 158 (1997) 3971-3977
36. Van der Poll T., Jansen P.M., Montegut W.J., Braxton C.C., Calvano S.E., Stackpole S.A., et al. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. J Immunol 158 (1997) 1971-1975
37. Suzuki T., Tahara H., Narula S., Moore K.W., Robbins P.D., and Lotze M.T. Viral interleukin-10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med 182 (1995) 477-486
38. Qin L., Chavin K.D., Ding Y., Tahara H., Favaro J.P., Woodward J.E., et al. Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival. J Immunol 156 (1996) 2316-2323
39. Zheng X.X., Steele A.W., Nickerson P.W., Steurer W., Steiger J., and Strom T.B. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol 154 (1995) 5590-5600
40. Mathisen P.M., Yu M., Johnson J.M., Drazba J.A., and Tuohy V.K. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J Exp Med 186 (1997) 159-164
41. Zheng X.X., Steele A.W., Hancock W.W., Stevens A.C., Nickerson P.W., Roy-Chaudhury P., et al. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol 158 (1997) 4507-4513
42. Grunig G., Corry D.B., Leach M.W., Seymour B.W.P., Kurup V.P., and Rennick D.M. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J Exp Med 185 (1997) 1089-1099
43. Kooy A.J., Prens E.P., van Heukelum A., Vuzevski V.D., van Joost T., and Tank B. Interferon-γ-induced ICAM-1 and CD40 expression, complete lack of HLA-DR and CD80 (B7.1), and inconsistent HLA-ABC expression in basal cell carcinoma: a possible role for interleukin-10?. J Pathol 187 (1999) 351-357
44. Redpath S., Angulo A., Gascoigne N.R., and Ghazal P. Murine cytomegalovirus infection down-regulates MHC class II expression on macrophages by induction of IL-10. J Immunol 162 (1999) 6701-6707
45. Chadban S.J., Tesch G.H., Foti R., Lan H.Y., Atkins R.C., and Nikolic-Paterson D.J. Interleukin-10 differentially modulates MHC class II expression by mesangial cells and macrophages in vitro and in vivo. Immunology 94 (1998) 72-78
46. Koppelman B., Neefjes J.J., de Vries J.E., and de Waal Malefyt R. Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 7 (1997) 861-871
47. Boorstein S.M., Elner S.G., Bian Z.M., Strieter R.M., Kunkel S.L., and Elner V.M. Selective IL-10 inhibition of HLA-DR expression in IFN-gamma-stimulated human retinal pigment epithelial cells. Curr Eye Res 16 (1997) 547-555
48. Yue F.Y., Dummer R., Geertsen R., Hofbauer G., Laine E., Manolio S., et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 71 (1997) 630-637